NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing NervGen (NASDAQ:NGEN) will ring the Nasdaq closing bell on January 22, 2026 in New York City to mark its recent Nasdaq listing. Adam Rogers, MD, Chairman and Interim CEO, will be joined by management, board members, advisors and guests. The ceremony broadcast begins at 3:45 pm ET and will be livestreamed from the Nasdaq MarketSite Tower and available on Nasdaq’s X and Facebook pages. The event highlights NervGen’s focus on developing neuroreparative therapeutics for spinal cord injury.

#NGEN #NGENF NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing

www.stocktitan.net/news/NGEN/nerv-gen-pharm...

NervGen Pharma Begins Trading on Nasdaq Today NervGen Pharma (NASDAQ:NGEN) announced its common shares began trading on Nasdaq on January 8, 2026. The company is a clinical-stage biopharmaceutical developer of neuroreparative therapeutics, advancing NVG-291 for spinal cord injury (SCI).Recent expanded Phase 1b/2a CONNECT SCI data (announced Nov 24, 2025) showed statistically significant improvements in upper-limb corticospinal signaling and reductions in hyperactive reticulospinal signaling, with reported durable functional and quality-of-life gains in chronic SCI. NervGen plans an FDA End-of-Phase 2 meeting in early 2026 to align on development and registration pathways.

#NGEN #NGENF NervGen Pharma Begins Trading on Nasdaq Today

www.stocktitan.net/news/NGEN/nerv-gen-pharm...